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Barrett’s esophagus is a condition characterized by the replacement of normal squamous epithelium 
in the esophagus with metaplastic columnar epithelium, and has a strong association with 
esophageal adenocarcinoma.  Because the incidence of esophageal adenocarcinoma continues to 
rise and its prognosis remains poor, patients with Barrett’s represent an identifiable high-risk group 
for targeted prevention efforts. 
Previous studies have suggested a possible protective effect for esophageal adenocarcinoma 
associated with the use of non-steroidal anti-inflammatory drugs (NSAIDS), but their use has not 
been formally recommended for cancer prevention. Statins, a group of drugs conventionally used to 
lower cholesterol, may also inhibit the progression of cancer, but they have not been as widely 
investigated with respect to esophageal cancers. 
Recently, graduate student Elizabeth Kantor and faculty supervisor Dr. Tom Vaughan from the 
Public Health Sciences Division published data from 395 participants of the Seattle Barrett’s 
Esophagus Study who were followed between 1995 and 2009, with a median four serial interviews 
and endoscopies. Seventy-two percent of participants reported NSAID use and thirty-five percent of 
participants reported statin use at baseline or during the follow-up period. 
Compared to non-use, statin use was associated with a 32 percent reduced risk (Hazard Ratio (HR) 
0.68; 95% Confidence Interval (CI) 0.30-1.54) of progression to esophageal adenocarcinoma in the 
overall sample after adjusting for age, sex, smoking and NSAID use.  In comparison, NSAID use 
was associated with a 38 percent reduction in risk (HR 0.62; 95% CI 0.34-1.10) after adjustment for 
the same covariates and statin use. In a relatively small subset (n=69) of patients with the highest 
risk of developing adenocarcinoma, those with high grade dysplasia, stain use was associated with a 
59 percent risk reduction (HR 0.41; 95% CI 0.13-1.26) while NSAID use was associated with 63 
percent risk reduction (HR 0.37; 95% CI 0.17-0.83). Further, in this particularly high-risk group (30 
cases esophageal adenocarcinoma), joint statin and NSAID use was associated with a statistically  
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significant 81 percent reduced risk (HR 0.19; 95% CI 0.06-0.64) compared to persons taking neither 
drug - a stronger effect than observed in participants using either class of drug on its own. 
Further work to better understand the mechanisms and effects of different sub-types, dosages, and 
periods of statin use among patients with Barrett’s esophagus will help determine the effectiveness 
of statins as potential chemoprotective agents, alone or in combination with NSAIDS. 
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A, Normal esophageal epithelium; B-D, variants of Barrett's esophagus 
 
 
